Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Pharmacol ; 15: 1357171, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38933679

RESUMO

Introduction: Polypharmacy, the use of multiple medications, is a growing concern among middle-aged and older patients, posing potential risks and challenges in healthcare management. Aim: This study aimed to identify the prevalence of polypharmacy and hyper-polypharmacy among populations of middle-aged vs. older patients and identify its associated common comorbidities and prescribed medications in Qatif Central Hospital (QCH), Saudi Arabia. Methods: Patients aged 40 years or older who presented to an outpatient medical care clinic at QCH, Saudi Arabia, between 1 January and 31 December 2021 were included, and their comorbidities, prescribed medications, and recent clinical laboratory test results were collected. The Charlson comorbidity index (CCI) score was calculated to predict the risk of mortality. Logistic regression was used to compute the association between the prevalence of polypharmacy and patient characteristics. The results were presented as odds ratios (ORs) and 95% confidence intervals (95% CIs). Results: A total of 14,081 patients were included; 31% of the cohort comprised older patients, and 66% of the cohort was identified with polypharmacy. The majority of the polymedicated patients were presented to an internal medicine care unit (34%). The prevalence of polypharmacy was positively associated with CCI (OR = 3.4, 95% CI 3.3-3.6), having a disease related to the musculoskeletal system (MSD) (OR = 4.2, 95% CI 3.8-4.7), and alimentary tract and metabolism (ATM) (OR = 3.8, 95% CI 3.4-4.2). Conversely, the prevalence of polypharmacy was negatively associated with age (OR = 0.9, 95% CI 0.89-0.91) and patients with cardiovascular diseases (OR = 0.6, 95% CI 0.5-0.7). Conclusion: Polypharmacy is still an ongoing concern. Patients, particularly those with diseases related to MSD or ATM, should be considered for reviewing prescriptions by pharmacists to reduce the risk of adverse drug reactions and future consequences of polypharmacy.

2.
Cancer Inform ; 22: 11769351231172589, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37223318

RESUMO

Iron is an essential cofactor needed for normal functions of various enzymes and its depletion lead to increase DNA damage, genomic instability, deteriorate innate, adaptive immunity, and promote tumor development. It is also linked to tumorigenesis of breast cancer cells through enhancing mammary tumor growth and metastasis. There is insufficient data describing this association in Saudi Arabia. This study aims to determine the prevalence of iron deficiency and its association with breast cancer among premenopausal and postmenopausal women referred for breast cancer screening center in Al Ahsa, Eastern Province of Saudi Arabia. Age, hemoglobin level, iron level, history of anemia, or iron deficiency were collected from patients' medical records. The included participants were grouped based on their age into premenopausal (<50 years) or postmenopausal (⩾50 years). The definition of low Hb implemented (Hb below 12 g/dL) and low total serum Iron levels (below 8 µmol/L). Logistic regression test was used to compute the association between having a positive cancer screening test (radiological or histocytological) and participant's lab results. The results are presented as odds ratios and 95% confidence intervals. Thrree hundred fifty-seven women were included, 77% (n = 274) of them were premenopausal. This group cases had more history of iron deficiency (149 [60%] vs 25 (30%), P = .001) compared to those in the postmenopausal group. The risk of having a positive radiological cancer screening test was associated with age (OR = 1.04, 95% CI 1.02-1.06), but negatively was associated with iron level (OR = 0.9, 95% CI 0.86-0.97) among the entire cohort. This study is the first to propose an association between iron deficiency and breast cancer among Saudi young females. This could suggest iron level as a new risk factor that may be used by clinicians to assess breast cancer risk.

3.
PLoS One ; 18(3): e0282399, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36857392

RESUMO

An increasing body of literature demonstrates the therapeutic relevance of polyphenols in eukaryotic cell and animal model studies. The phase II glutathione S-transferases (GST) show differential responses to thymoquinone, a major bioactive polyphenol constituent of the black seed, Nigella sativa. Beyond antioxidant defense, GSTs may act in non-enzymatic capacities to effect cell cycle, motility, and differentiation. Here, we report the impact of thymoquinone on the life cycle of the eukaryotic model Dictyostelium discoideum and accompanying profiles of its GST-alpha (DdGSTA) enzyme activity and isozyme expression. In silico molecular modeling revealed strong interaction(s) between thymoquinone and DdGSTA2 and DdGSTA3 isozymes that correlated with in vivo, dose-dependent inhibition of cell proliferation of amoebae at 24, 48, and 72hr. Similarly, cytosolic DdGST enzyme activity (CDNB activity) was also responsive to different thymoquinone concentrations. Thymoquinone generally reduced expression of DdGSTA2 and DdGSTA3 isozymes in proliferating cells, however differential expression of the isozymes occurred during starvation. Thymoquinone effectively reduced early-stage aggregation of starved amoeba, accompanied by increased reactive oxygen species and altered expression of tubulin and contact site A (gp80), which resulted in reduced morphogenesis and fruiting body formation. These observations reveal that thymoquinone can impact signaling mechanisms that regulate proliferation and development in D. discoideum.


Assuntos
Dictyostelium , Células Eucarióticas , Animais , Eucariotos , Isoenzimas , Quimiotaxia , Proliferação de Células , Glutationa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...